Technical Analysis for ARRY - Array BioPharma Inc.

Grade Last Price % Change Price Change
grade A 17.53 0.46% 0.08
ARRY closed up 0.46 percent on Friday, January 18, 2019, on approximately normal volume.

Earnings due: Feb 5

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ARRY trend table...

Date Alert Name Type % Chg
Jan 18 Pocket Pivot Bullish Swing Setup 0.00%
Jan 18 Wide Bands Range Expansion 0.00%
Jan 17 Pocket Pivot Bullish Swing Setup 0.46%
Jan 17 Wide Bands Range Expansion 0.46%
Jan 17 Overbought Stochastic Strength 0.46%
Jan 16 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 4.22%
Jan 16 Wide Bands Range Expansion 4.22%
Jan 16 Overbought Stochastic Strength 4.22%
Jan 15 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 1.27%
Jan 15 Pocket Pivot Bullish Swing Setup 1.27%

Older signals for ARRY ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Its proprietary clinical programs include ARRY-520, a kinesin spindle protein inhibitor, which is in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie2 dual inhibitor that is in Phase 1 clinical trial for the treatment of myelodysplastic syndromes; ARRY-797, a p38 inhibitor, which is in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist that is in Phase 2 clinical trial for asthma. The company's partnered clinical programs comprise drug candidates for the treatment of cancer, including MEK162, an MEK inhibitor in Phase 3 clinical trial; Selumetinib, an MEK inhibitor in Phase 2/pivotal clinical trial; and GDC-0068 AKT inhibitor, LY2606368 Chk-1 inhibitor, and VTX-2337 toll-like receptor in Phase 2 clinical trial. Its partnered clinical programs also include Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 clinical trial; ARRY-543/ASLAN001, a HER2/EGFR inhibitor for gastric cancer in Phase 2 clinical trial; GDC-0575 and GDC-0425 Chk-1 inhibitors for cancer in Phase 1b clinical trial; ARRY-380, an HER2 inhibitor in Phase 1 clinical trial for breast cancer; and GDC-0994 in a Phase 1 dose-escalation study in patients with locally advanced or metastatic solid tumors. The company has collaborations with Amgen Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Eli Lilly and Company; Genentech Inc.; Novartis International Pharmaceutical Ltd.; Oncothyreon Inc.; and VentiRx Pharmaceuticals, Inc. for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Is ARRY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 20.21
52 Week Low 12.56
Average Volume 2,605,833
200-Day Moving Average 15.5567
50-Day Moving Average 15.8044
20-Day Moving Average 15.8585
10-Day Moving Average 17.357
Average True Range 0.8919
ADX 24.39
+DI 27.2684
-DI 12.6843
Chandelier Exit (Long, 3 ATRs ) 15.5143
Chandelier Exit (Short, 3 ATRs ) 15.7357
Upper Bollinger Band 19.0102
Lower Bollinger Band 12.7068
Percent B (%b) 0.77
BandWidth 39.747769
MACD Line 0.6093
MACD Signal Line 0.4419
MACD Histogram 0.1674
Fundamentals Value
Market Cap 3 Billion
Num Shares 171 Million
EPS -0.72
Price-to-Earnings (P/E) Ratio -24.35
Price-to-Sales 41.12
Price-to-Book 153.97
PEG Ratio -1.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.57
Resistance 3 (R3) 18.61 18.31 18.40
Resistance 2 (R2) 18.31 18.04 18.29 18.34
Resistance 1 (R1) 17.92 17.88 18.11 17.88 18.28
Pivot Point 17.61 17.61 17.71 17.59 17.61
Support 1 (S1) 17.22 17.35 17.42 17.18 16.78
Support 2 (S2) 16.92 17.18 16.90 16.72
Support 3 (S3) 16.53 16.92 16.66
Support 4 (S4) 16.49